Evidence map›Paper›PMID 28077417›Full record

ArticleBlood2017

Hiroyoshi Kunimoto, Anna Sophia McKenney, Cem Meydan, Kaitlyn Shank, Abbas Nazir, Franck Rapaport, Benjamin Durham, Francine E Garrett-Bakelman, Elodie Pronier, Alan H Shih and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Mechanisms that regulate the activities of TET proteins.Cellular and molecular life sciences : CMLS · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Epigenetic Clock: DNA Methylation in Aging.Stem cells international · 2020
    Review
  12. Article
  13. Hematopoietic stem cells under pressure.Current opinion in hematology · 2017
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Hiroyoshi KunimotoHuman Oncology and Pathogenesis Program.
Anna Sophia McKenneyHuman Oncology and Pathogenesis Program.
Cem MeydanInstitute for Computational Biomedicine.
Kaitlyn ShankHuman Oncology and Pathogenesis Program.
Abbas NazirHuman Oncology and Pathogenesis Program.
Franck RapaportHuman Oncology and Pathogenesis Program.
Benjamin DurhamHuman Oncology and Pathogenesis Program.
Francine E Garrett-BakelmanDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY.
Elodie PronierHuman Oncology and Pathogenesis Program.
Alan H ShihHuman Oncology and Pathogenesis Program.
Ari MelnickDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY.
Jayanta ChaudhuriImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Ross L LevineHuman Oncology and Pathogenesis Program.
Memorial Sloan Kettering Cancer Center · USCornell University · USInstitute for Biomedicine · ITTri-Institutional PhD Program in Chemical Biology · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Mechanistic Elucidation of Class Switch Recombination and Somatic HypermutationR01AI072194 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI CHAUDHURI, JAYANTA · 2009 to 2025
$6.9M
Role of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3M
RNA-directed targeting of AID in immunity and genomic integrityR01AI124186 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Jayanta Chaudhuri · 2016 to 2026
$4.8M
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid LeukemiaR01CA198089 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARROLL, MARTIN · 2015 to 2019
$3.3M
Analysis of TET2 function in acute leukemiaK08CA181507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHIH, ALAN · 2016 to 2020
$900k
Genetic and epigenetic basis of relapse in acute myeloid leukemiaK08CA169055 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GARRETT-BAKELMAN, FRANCINE EVALINA · 2012 to 2016
$742k
Modeling Transformation: Myeloproliferative Neoplasms to Acute Myeloid LeukemiaF30CA183497 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MCKENNEY, ANNA SOPHIA · 2014 to 2017
$193k
NCI NIH HHS K08 CA169055NCI NIH HHS K08 CA181507NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA198089NIAID NIH HHS R01 AI072194NIAID NIH HHS R01 AI124186NIGMS NIH HHS T32 GM007739
6 · The paper itself

Abstract

Recent studies have reported that activation-induced cytidine deaminase (AID) and ten-eleven-translocation (TET) family members regulate active DNA demethylation. Genetic alterations of

Indexed as

Cell DifferentiationDNA MethylationAICDA (Activation-Induced Cytidine Deaminase)AnimalsCell LineageCell Self RenewalCell Transformation, NeoplasticCytidine DeaminaseDioxygenasesDNA-Binding ProteinsErythroid CellsGene SilencingHematopoietic Stem CellsHumansMiceMyeloid CellsAICDA (Activation-Induced Cytidine Deaminase)Cytidine DeaminaseDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanTet2 protein, mouse

Identifiers

PMID28077417
PMCPMC5374286
OpenAlexW2572813173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.